Edwards Lifesciences Corp (EW)vsInogen Inc (INGN)
EW
Edwards Lifesciences Corp
$91.78
+1.06%
HEALTHCARE · Cap: $49.92B
INGN
Inogen Inc
$7.26
+0.14%
HEALTHCARE · Cap: $186.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1738% more annual revenue ($6.51B vs $354.30M). EW leads profitability with a 15.4% profit margin vs -6.9%. EW appears more attractively valued with a PEG of 1.85. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
INGN
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$91.78
$159.67 discount
Margin of Safety
+88.7%
Fair Value
$54.30
Current Price
$7.26
$47.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Reasonable price relative to book value
Earnings expanding 87.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
3.0% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : INGN
The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.5x leaves little room for execution misses.
Bear Case : INGN
The primary concerns for INGN are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
EW profiles as a mature stock while INGN is a turnaround play — different risk/reward profiles.
INGN carries more volatility with a beta of 1.50 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 49/100), backed by strong 15.4% margins and 13.6% revenue growth. INGN offers better value entry with a 88.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Inogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?